Ligand Pharmaceuticals Incorporated (LGND)
Automate Your Wheel Strategy on LGND
With Tiblio's Option Bot, you can configure your own wheel strategy including LGND - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LGND
- Rev/Share 9.4569
- Book/Share 41.4535
- PB 2.7419
- Debt/Equity 0.0056
- CurrentRatio 5.271
- ROIC -0.06
- MktCap 2192978772.0
- FreeCF/Share 1.8502
- PFCF 61.7619
- PE -16.4471
- Debt/Assets 0.0049
- DivYield 0
- ROE -0.1636
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | LGND | Stifel | -- | Buy | -- | $143 | April 10, 2025 |
| Initiation | LGND | Oppenheimer | -- | Outperform | -- | $135 | Oct. 3, 2024 |
News
Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward
Published: June 24, 2025 by: Seeking Alpha
Sentiment: Positive
I maintain my Buy rating on Ligand Pharmaceuticals due to its strong growth trajectory and diversified portfolio. Ligand offers investors exposure to dozens of therapies, reducing risk and increasing upside potential. LGND's business model supports sustainable revenue through royalties and partnerships with leading pharma firms.
Read More
Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Melanie Herman – Executive Director-Investor Relations Todd Davis – Chief Executive Officer Rich Baxter – Senior Vice President-Investment Operations Tavo Espinoza – Chief Financial Officer Lauren Hay – Vice President-Strategic Planning and Investment Analytics Conference Call Participants Doug Miehm – RBC Capital Markets Matt Hewitt – Craig-Hallum Trevor Allred – Oppenheimer Annabel Samimy – Stifel John Vandermosten – Zacks Operator Thank you for standing by. My name is Kate and I will be your conference operator today.
Read More
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share 1 of $6.00-$6.25 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla.
Read More
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors invested $25 million in return for a high-single digit royalty on D-Fi JUPITER, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has closed a royalty financing agreement with Castle Creek Biosciences, Inc. to support the Phase 3 clinical study of D-Fi (FCX-007), Castle Creek's lead candidate, in patients with dystrophic epidermolysis bullosa (DEB).
Read More
About Ligand Pharmaceuticals Incorporated (LGND)
- IPO Date 1992-11-18
- Website https://www.ligand.com
- Industry Biotechnology
- CEO Todd C. Davis
- Employees 68